171 related articles for article (PubMed ID: 27439864)
1. Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma.
Metz HE; Kargl J; Busch SE; Kim KH; Kurland BF; Abberbock SR; Randolph-Habecker J; Knoblaugh SE; Kolls JK; White MF; Houghton AM
Proc Natl Acad Sci U S A; 2016 Aug; 113(31):8795-800. PubMed ID: 27439864
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.
Hill KS; Erdogan E; Khoor A; Walsh MP; Leitges M; Murray NR; Fields AP
Oncogene; 2014 Apr; 33(16):2134-44. PubMed ID: 23604119
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
4. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.
Baldelli E; Bellezza G; Haura EB; Crinó L; Cress WD; Deng J; Ludovini V; Sidoni A; Schabath MB; Puma F; Vannucci J; Siggillino A; Liotta LA; Petricoin EF; Pierobon M
Oncotarget; 2015 Oct; 6(32):32368-79. PubMed ID: 26468985
[TBL] [Abstract][Full Text] [Related]
5. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
Mohrherr J; Haber M; Breitenecker K; Aigner P; Moritsch S; Voronin V; Eferl R; Moriggl R; Stoiber D; Győrffy B; Brcic L; László V; Döme B; Moldvay J; Dezső K; Bilban M; Popper H; Moll HP; Casanova E
Int J Cancer; 2019 Dec; 145(12):3376-3388. PubMed ID: 31407334
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth.
Houghton AM; Rzymkiewicz DM; Ji H; Gregory AD; Egea EE; Metz HE; Stolz DB; Land SR; Marconcini LA; Kliment CR; Jenkins KM; Beaulieu KA; Mouded M; Frank SJ; Wong KK; Shapiro SD
Nat Med; 2010 Feb; 16(2):219-23. PubMed ID: 20081861
[TBL] [Abstract][Full Text] [Related]
7. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
[TBL] [Abstract][Full Text] [Related]
8. Ablation of insulin receptor substrates 1 and 2 suppresses
Xu H; Lee MS; Tsai PY; Adler AS; Curry NL; Challa S; Freinkman E; Hitchcock DS; Copps KD; White MF; Bronson RT; Marcotrigiano M; Wu Y; Clish CB; Kalaany NY
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):4228-4233. PubMed ID: 29610318
[TBL] [Abstract][Full Text] [Related]
9. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
Cho HC; Lai CY; Shao LE; Yu J
Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
[TBL] [Abstract][Full Text] [Related]
10. CD44 promotes Kras-dependent lung adenocarcinoma.
Zhao P; Damerow MS; Stern P; Liu AH; Sweet-Cordero A; Siziopikou K; Neilson JR; Sharp PA; Cheng C
Oncogene; 2013 Oct; 32(43):5186-90. PubMed ID: 23208496
[TBL] [Abstract][Full Text] [Related]
11. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
12. Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma.
Ali SA; Justilien V; Jamieson L; Murray NR; Fields AP
Cancer Cell; 2016 Mar; 29(3):367-378. PubMed ID: 26977885
[TBL] [Abstract][Full Text] [Related]
13. EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.
Clay TD; Russell PA; Do H; Sundararajan V; Conron M; Wright GM; Solomon B; Dobrovic A; McLachlan SA; Moore MM
Med Oncol; 2017 Sep; 34(10):175. PubMed ID: 28879441
[TBL] [Abstract][Full Text] [Related]
14. Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.
Wang Y; Hou N; Cheng X; Zhang J; Tan X; Zhang C; Tang Y; Teng Y; Yang X
Int J Biol Sci; 2017; 13(5):652-659. PubMed ID: 28539837
[TBL] [Abstract][Full Text] [Related]
15. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
Chen N; Fang W; Lin Z; Peng P; Wang J; Zhan J; Hong S; Huang J; Liu L; Sheng J; Zhou T; Chen Y; Zhang H; Zhang L
Cancer Immunol Immunother; 2017 Sep; 66(9):1175-1187. PubMed ID: 28451792
[TBL] [Abstract][Full Text] [Related]
17. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.
Ambrogio C; Gómez-López G; Falcone M; Vidal A; Nadal E; Crosetto N; Blasco RB; Fernández-Marcos PJ; Sánchez-Céspedes M; Ren X; Wang Z; Ding K; Hidalgo M; Serrano M; Villanueva A; Santamaría D; Barbacid M
Nat Med; 2016 Mar; 22(3):270-7. PubMed ID: 26855149
[TBL] [Abstract][Full Text] [Related]
19. Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.
Zhang J; Park D; Shin DM; Deng X
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):11-6. PubMed ID: 26578706
[TBL] [Abstract][Full Text] [Related]
20. Cytomorphological identification of advanced pulmonary adenocarcinoma harboring KRAS mutation in lymph node fine-needle aspiration specimens: Comparative investigation of adenocarcinoma with KRAS and EGFR mutations.
Song DH; Lee B; Shin Y; Choi IH; Ha SY; Lee JJ; Hong ME; Choi YL; Han J; Um SW
Diagn Cytopathol; 2015 Jul; 43(7):539-44. PubMed ID: 25427298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
